Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Letter

Response to 'Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways'

Cengiz Korkmaz

Author Affiliations

Department of Internal Medicine, Division of Rheumatology, Eskişehir Osmangazi University, Vişnelik Mah, Alifuat Güven Cad, Akasya Sok. 11/11 Eskişehir, Turkey

Arthritis Research & Therapy 2012, 14:402  doi:10.1186/ar3862


See related research by Koskinen et al., http://arthritis-research.com/content/13/6/R184

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/3/402


Published:21 June 2012

© 2012 BioMed Central Ltd

Letter

Different mechanisms and mediators in different stages of osteoarthritis (OA) may be involved in progression of the disease. Cross-sectional studies performed regarding cartilage degradation in OA may therefore not be generalised to whole stages. Koskinen and colleagues' study should be evaluated in light of this knowledge [1].

I read with great interest Koskinen and colleagues' article about the role of adiponectin on cartilage degradation in OA [1]. The authors showed that plasma adiponectin levels and adiponectin released from OA cartilage were higher in patients with the radiographically more severe OA. They suggested that adiponectin is associated with cartilage destruction in OA [1]. Making an extrapolation based on a cross-sectional study in order to account for the mechanism of cartilage degradation in OA, however, may not be very accurate.

Chondrocytes are often believed to exhibit aberrant behaviour and shift to other phenotypes such as anabolic, catabolic or hypertrophic phenotypes over the course of the disease, upon physiological and mechanical stress [2]. The level of biochemical markers and mediators involved in the OA process differ for each one of these phases [3]. Some of these mediators are directly involved in the progression of the OA process or they may be secondary changes in the course of OA. Koskinen and colleagues showed that plasma adiponectin levels were higher in patients with grade IV and V disease than those in patients with grade I, II and III disease (Ahlback classification) [1]. It is my belief that these results do not lead us to conclude that adiponectin could be accountable for degradation of the cartilage. Rather, increased levels of adiponectin may be a secondary phenomenon to the late stage of OA, which could be deemed an indication of severity. Another explanation could be that increased levels of adiponectin may serve as a protective response to the catabolic process in OA. The current understanding of cytokines and growth factors has been shown incapable of determining a single factor that could be responsible for all chondrocyte responses [3].

Another point to be raised in this study would be the effect of adiponectin on OA cartilage and primary chondrocytes in vitro. Koskinen and colleagues reported that adiponectin enhanced nitric oxide, IL-6, matrix metalloproteinase-1 and matrix metalloproteinase-3 production in primary OA chondrocytes in a dose-dependent manner [1]. However, the authors only investigated factors involved in the degradation of cartilage. Adiponectin may have a dual effect on cartilage homeostasis, because it may also stimulate anabolic mediators such as tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 in addition to catabolic mediators [4]. Adiponectin may be involved in the joint metabolism by changing the balance of matrix metalloproteinases and tissue inhibitors of metalloproteinases [4].

In a cross-sectional study, as a result, studying a single molecule does not solve the mystery of cartilage destruction. A more versatile approach is required to determine the mechanism of cartilage destruction in OA.

Abbreviations

IL: interleukin; OA: osteoarthritis.

Competing interests

The author declares that they have no competing interests.

References

  1. Koskinen A, Juslin S, Nieminen R, Moilanen T, Vuolteenaho K, Moilanen E: Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways.

    Arthritis Res Ther 2011, 13:R184. PubMed Abstract | BioMed Central Full Text OpenURL

  2. Bay-Jensen AC, Hoegh-Madsen S, Dam E, Henriksen K, Sondergaard BC, Pastoureau P, Qvist P, Karsdal MA: Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis.

    Rheumatol Int 2010, 30:435-442. PubMed Abstract | Publisher Full Text OpenURL

  3. Aigner T, Kurz B, Fukui N, Sandel L: Roles of chondrocytes in the pathogenesis of osteoarthritis.

    Curr Opin Rheumatol 2002, 14:578-584. PubMed Abstract | Publisher Full Text OpenURL

  4. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH: Evidence for a protective role for adiponectin in osteoarthritis.

    Biochim Biophys Acta 2006, 1762:711-718. PubMed Abstract | Publisher Full Text OpenURL